CClinicalTrials.gg
RecruitingNCT07119437LILYBETUpdated Jun 18, 2026

Low Impact Laparoscopy In Bariatric Surgery

An interventional study of low pneumoperitoneum laparoscopy with microsurgery and standard laparoscopy in Obesity, Morbid, sponsored by Fondazione Policlinico Universitario Campus Bio-Medico. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Fondazione Policlinico Universitario Campus Bio-Medico · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if low pressure pneumoperitoneum and small incisions (low impact laparoscopy, LIL) works to reduce pain and improve pulmonary function in patients underwent to bariatric surgery.

It will also learn about the safety and patients' satisfaction of the procedure. The main questions it aims to answer are:

Does LIL lower post surgical pain and improve pulmonary function? Is LIL safe for obese patients? Researchers will compare LIL to standard laparoscopy performing sleeve gastrectomy in patients with obesity.

Participants will:

be randomised to LIL group or standard laparoscopy. After the operation the researchers will evaluate the pain and the efficiency of lung ventilation at pre-established intervals. after 3 months the patients will complete a questionnaire on aesthetic satisfaction and overall satisfaction.

02

Conditions studied

  • Obesity, Morbid

Keywords

  • obesity
  • low impact laparoscopy
  • sleeve gastrectomy
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age between 18 years-old and 65 years-old
  • BMI (Body Mass Index) >35 Kg/m2 and \< 45 Kg/m2;
  • Patients candidate to sleeve gastrectomy

Exclusion criteria

Exclusion Criteria:

  • Patients with neurological and/or psychiatric disorders
  • Patients with Chronic Pain Syndrome
  • Patients with a history of surgical procedures using a laparotomic approach in the upper abdominal quadrants
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Low Pneumoperitoneum Laparoscopy with microsurgery

    Procedure: low pneumoperitoneum laparoscopy with microsurgery

  • Active comparator
    standard laparoscopy

    Procedure: standard laparoscopy

Interventions

  • Procedurelow pneumoperitoneum laparoscopy with microsurgery

    Use of low pressure for pneumoperitoneum (8-10 mmHg) and mini surgical access for bariatric procedure (sleeve gastrectomy).

  • Procedurestandard laparoscopy

    Standard laparoscopy (12-14 mmHg) and normal surgical access for bariatric procedures (sleeve gastrectomy).

05

What researchers measure

Primary outcomes

  1. POST OPERATIVE PAIN

    Post-operative pain (AS REST PAIN AND MOVIMENT PAIN) will be assessed using the Numeric Pain Rating Scale (NRS), which rates pain from 0 to 10. 0 is defined as no pain, while 10 represents the maximum pain. 0 is the best result, 10 the worst. The questionnaire will be administered in the PACU and at 6, 12, 24, and 36 hours after the end of the procedure.

    Time frame: FROM THE ENTER IN PACU TO 36 HOURS POST- SURGERY

  2. Pulmonary performance

    Efficiency of ventilation will be evaluated recording the values of Maximum Inspiratory Pressure (MIP), maximum expiratory pressure (MEP), Peak expiratory flow (PEF)

    Time frame: from surgery to 24 hours post-surgery

Secondary outcomes

  1. USE OF Analgesics

    Comparison of analgesic use between the two groups during post-operative recovery

    Time frame: from surgery to 36 hours post-surgery

  2. operative time

    Comparison of opertive time between the two groups

    Time frame: from the surgical incision to the last skin stitch

  3. Rate of conversion to standard laparoscopy

    Record the number of cases in the operative group where conversion to a standard laparoscopic approach was necessary, with pressure values \> 10 mmHg for more than 20% of the duration of the procedure. Also analyzing the results for BMI subgroups.

    Time frame: from the beginning of surgery to the end of surgery

  4. Rate of laparotomy conversion

    Number of cases in which the surgical procedure had to be converted from laparoscopy to an open approach.

    Time frame: from the beginning of surgery to the end of surgery

  5. Ambulation Time

    Comparison of mobilization time between the two groups

    Time frame: From the end of surgery up to 24 hours post-surgery

  6. The time to first flatus

    Compare the time to intestinal motility recovery between the two groups.

    Time frame: From the end of surgery up to 48 hours post-surgery

  7. Liver Function

    Comparison between the two groups of liver function tests that include alanine transaminase (ALT, Normal values 0-55 U/L) , aspartate transaminase (AST, normal values 5-34 U/L), alkaline phosphatase (ALP normal values 53-141 U/L) and gamma-glutamyl transferase (GGT, normal values 8-33 U/L).

    Time frame: first and second post-operative day

  8. Post-operative hospital stay

    Post-operative hospital stay

    Time frame: from the day of surgery up to 30 days

  9. Postoperative complications

    All postoperative complications

    Time frame: from surgery to 30 days after surgery

  10. First Operator Comfort

    Evaluate the comfort of the operating surgeon related to the adequate exposure of the surgical field during the procedure using a 5-point surgical rating scale for laparoscopic surgical workspace. The scale ranges from 1 to 5, where 1 corresponds to the worst possible outcome, while 5 represents the best possible outcome.

    Time frame: during surgery

  11. Aesthetic satisfaction

    Evaluate the degree of aesthetic and overall satisfaction of patients by administering to them, 3 months after the intervention, the Patient Scar Assessment Scale (PSAS), a validated tool for scar assessment, and the Ultimate Question (UQ), related to overall satisfaction. These tests are administered together and the patient, who responds to 8 different items, assigning a score from 1 to 10. The maximum test score is 80, indicating the highest satisfaction, while the minimum score is 8, corresponding to the worst possible outcome.

    Time frame: from surgery to 3-month post surgery

06

Study locations

1 of 1 sites recruiting
  • Policlinico Campus Bio-Medico
    Rome, Italy 00128, Italy
    • Chiara Isabella Miligi, General surgeon's Degree · Contact · +393891015712
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07119437
Lead sponsor
Fondazione Policlinico Universitario Campus Bio-Medico
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Feb 4, 2025
Primary completion
Sep 4, 2026 (estimated)
Completion
Oct 4, 2026 (estimated)
Last update
Jun 18, 2026

Study contacts

Vincenzo Bruni
Contact
v.bruni@policlinicocampus.it
+39 3484064965
Ida Francesca Gallo
Contact
i.gallo@policlinicocampus.it
+393926237399

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion